Acceleron's blood disorder drug candidate wins orphan status

03/27/2013 | Boston Herald

The FDA has given orphan-drug status to Acceleron Pharma's experimental beta-thalassemia and myelodysplastic syndrome treatment ACE-536. The red blood cell booster is being developed by Acceleron in partnership with Celgene.

View Full Article in:

Boston Herald

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA
Catheter Engineer
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
MANAGER MEDICAL GAS COMPLIANCE AND SAFETY
Matheson Tri-Gas, Inc.
Houston, TX
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations